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Abstract
Introduction. Survival following resection for pancreatic ductal adenocarcinoma (PDAC) remains poor. The aim of this
study was to validate a survival nomogram designed at the Memorial Sloan-Kettering Cancer Centre (MSKCC) in a UK
tertiary referral centre. Methods. Patients who underwent resection for PDAC between 1995 and 2005 were analysed
retrospectively. Standard prognostic factors and nomogram-specific data were collected. Continuous data are presented as
median (inter-quartile range). Results. Sixty-three patients were analysed. The median survival was 326 (209680) days. On
univariate analysis lymph node status (node ve 297 (194471) days versus node ve 367 (3081060) days, p0.005)
and posterior margin involvement (margin ve 210 (146443) days versus margin ve 355 (265835) days, p0.024)
were predictors of a poor survival. Only lymph node positivity was significant on multivariate analysis (p0.006). The
median nomogram score was 217 (198236). A nomogram score of 113217 predicted a median survival of 367 (295847)
days compared to 265 (157443) days for a score of 218269, p0.012. Conclusion. Increasing nomogram score was
associated with poorer survival. However the accuracy demonstrated by MSKCC could not be replicated in the current
cohort of patients and may reflect differences in patient demographics, accuracy of pathological staging and differences in
treatment regimens between the two centres.
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Introduction
Long-term survival following potentially curative re-
section for pancreatic ductal adenocarcinoma (PDAC)
remains poor with a median survival of 1218 months
[19] and few actual five-year survivors [1]. Surgery
combined with adjuvant therapies offers the only
prospect of long-term cure. Although with the advent
of specialised centres the mortality following pancrea-
ticoduodenectomy has fallen to less than 5%, early
postoperative morbidity remains high [10] and it takes
three to six months for quality of life measures to
return to normal [11,12]. Therefore, identifying those
patients with a poor prognosis and short life expec-
tancy may prove advantageous when counselling
patients and their relatives regarding potential ther-
apeutic and non-therapeutic interventions.
Nomograms are mathematical models which utilise
prognostic variables in an attempt to calculate
percentage survival in the short and long term.
They have been used to predict survival in patients
with sarcomas, and those with gastric, colorectal,
lung and prostate cancer [1317]. A prognostic
nomogram for pancreatic cancer (Figure 1) was
developed from a large cohort of patients in the
Memorial Sloan-Kettering Cancer Centre
(MSKCC). The purpose of this nomogram was to
determine the probability that patients undergoing
resection for PDAC would be alive at one, two and
three years postoperatively and to provide more
accurate prognostic information than the conven-
tional TNM system, which is non-discriminatory
[18].
The aim of the present study was to validate the
accuracy of the MSKCC pancreatic cancer nomo-
gram against an independent data series from a UK
tertiary referral centre.
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Methods
Patients who underwent resection for histologically
confirmed PDAC at the Royal Infirmary of Edinburgh
from January 1995 to January 2005 were analysed.
Exclusion criteria included patients who had died
within 30 days of surgery.
Patients were identified from a prospective database
and data was supplemented by retrospective case note
review. Standard prognostic factors and nomogram-
specific data were collected including clinical factors
(age, sex, weight loss, back pain), operative details
(pancreaticoduodenectomy, distal pancreatectomy,
splenectomy, portal vein resection) and pathological
factors (resection margin status (malignant cells
51 mm of radial or surgical margin (margin positive
(ve)) or margin negative (ve)), posterior resection
margin status, differentiation, number of nodes with
metastatic involvement (nodeve or nodeve), total
number of nodes resected, T-stage, tumour size).
Weight loss was defined as objective loss of weight
as recorded in the database or in clinical correspon-
dence. Outcome data included survival from time of
operation and the total nomogram score, calculated
for each patient using the MSKCC nomogram [18].
Using the nomogram a score was determined for
each patient and the median nomogram score was
calculated for the cohort of Edinburgh patients. The
predicted versus actual survival, based on the median
nomogram score, was then calculated.
Statistical analysis was performed using Statview
software (version 5.0.1). All data are presented as
median (inter-quartile range). Kaplan-Meier survival
curves were created. Uni- and multivariate analysis
were performed using the log rank test and Cox-
proportional hazards method, respectively to identify
independent prognostic factors. The significance of
differences between actual versus predicted survival
were assessed using the Chi-squared test or Fisher
exact test where appropriate. A p-value ofB0.05 was
deemed significant.
Results
Sixty-three patients (37 male, 26 female) with a
median age of 65 (5971) years were included in the
study. In three patients, the presence or absence of
weight loss was not recorded and in one patient the
presence or absence of back pain was not recorded. In
these cases the median nomogram score was inputted
in place of missing data points rather than excluding
patients as this was found to have no effect on the total
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Figure 1. MSKCC nomogram: Example demonstrating the percentage of survival according to nomogram score (Brennan et al. 2004).
Table I. Demographics of MSKCC/Edinburgh patients.
MSKCC (n555) Edinburgh (n63)
Mean age 65 64
Male gender 50% 59%
Portal vein resection 14% 0%
Splenectomy 10% 2%
Resection margin positive 21% 38%
Pancreatic head resection
versus other
89% 98%
Poorly differentiated 28% 48%
Posterior resection margin
positive
14% 32%
Back pain 14% 6%
Weight loss 54% 83%
Mean number of positive
lymph nodes
2.1 1.9
Mean number of negative
lymph nodes
16.9 6.4
Tumour diameter2 cm Not reported 22%
Chemotherapy Not uniform One patient
30-day mortality 2.8% 4.7%
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nomogram score. Sixty-two patients (98%) under-
went pancreaticoduodenectomy and one patient (2%)
underwent a distal pancreatectomy and splenectomy.
No portal vein resections were performed. The
demographic data for Edinburgh patients in compar-
ison to MSKCC patients is shown in Table I. The
median survival was 326 (209680) days with the
longest survivor having lived 1330 days (three years
and seven months approximately).
Twenty patients (32%) had positive posterior resec-
tion margins and 45 patients (69%) were lymph node
positive. On univariate analysis, lymph node status
(nodeve 297 (194471) days versus node ve 367
(3081060) days, p0.005) and posterior margin
involvement (posterior margin ve 210 (146443)
days versus posterior margin ve 355 (265835)
days, p0.024) were predictors of a poor survival
(Figure 2 and Figure 3). However on multivariate
analysis only lymph node status remained an inde-
pendent predictor of survival (pB0.006) (Table II). A
nomogram score of less than 217 predicted a median
survival of 367 (295847) days compared to 265
(157443) days for a nomogram score of 218 or
greater, p0.012 (Figure 4).
The actual survival of Edinburgh patients at 12, 24
and 36 months was plotted against predicted survival
based on the median nomogram score (217) of the
group (Figure 5). Edinburgh patients were found to
have a shorter survival than predicted by the nomo-
gram. Taking the median score of 217, the nomogram
predicted that 63% of Edinburgh patients would have
survived at one year but only 44% actually survived
(p0.021). At two years the nomogram predicted
that 28% would survive but only 24% actually
survived (p0.23). At three years the nomogram
predicted that 15% of patients would survive but only
8% actually survived (p0.04).
Discussion
The results of this study confirm the poor prognosis
associated with PDAC even after potentially curative
resection. Well-established prognostic factors in pa-
tients undergoing resection for PDAC include tumour
differentiation, resection margin status, tumour size
and nodal involvement [27] although in the current
cohort of patients only lymph node positivity re-
mained significant on multivariate analysis. This was
also found to be a highly significant prognostic factor
by the MSKCC group.
An increasing nomogram score was shown to be
associated with poorer survival (Figure 4). However,
the accuracy of the nomogram reported by the
MSKCC group could not be replicated in the current
cohort of patients. This may have been due to the
relatively small sample size. The overall actual survival
of Edinburgh patients was found to be consistently
less than the predicted survival using the nomogram,
based on the median nomogram score of 217 for the
group (Figure 5). There are several possible explana-
tions for this. Although the patient groups appear
different at baseline with more patients having positive
resection margins, poorly differentiated tumours and
weight loss at presentation (Table I), all of these
factors are included in the nomogram and therefore it
is unlikely that these account for the results.
It should be noted that some pathological defini-
tions may differ slightly between the USA and the UK
and this may lead to inaccurate nomogram scoring.
For example, the posterior resection margin is also
variously known as the mesenteric, uncinate or retro-
peritoneal margin [1922]. In the USA, the posterior
resection margin has been defined as the adipose
tissue dorsal and lateral to the superior mesenteric
artery [2225]. However, the UK pathological guide-
lines define the posterior resection margin as the
tissue immediately posterior to the head of the
pancreas and also describe the medial pancreatic (or
superior mesenteric vein) margin [19]. Although the
definitions of the posterior resection margin are
essentially similar, they could be misinterpreted,
justifying pleas for standardisation of pathological
reporting for resected tumours in the head of pancreas
[21,26,27]. Invasion specifically of the posterior
resection margin has previously been identified as an
adverse prognostic factor [8,9,20] and so differences
in pathological reporting may have affected the
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Figure 2. Effect of lymph node positivity on survival (Edinburgh).
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Figure 3. Effect of posterior margin invasion on survival (Edin-
burgh).
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nomogram results. It is important that reporting of
such prognostic factors is standardised to allow
accurate comparison between centres.
Although it would appear that the surgery per-
formed at MSKCC may have been more extensive
with a higher number of portal vein resections
performed and an increased median number of nodes
per specimen identified (Table I), it is recognised that
lymph node count is often related to the quality of
pathological reporting. This is important as the
Edinburgh patients may have been understaged which
would result in a worse actual survival compared with
predicted survival.
However, perhaps the most important difference
between the patient groups was in the use of adjuvant
therapies. Only one patient in the current series
received adjuvant chemotherapy, as it was not a
standard practice in the UK during the time period
of the study, whereas a greater proportion of the
MSKCC patients received some form of adjuvant
therapy. The optimal use of adjuvant therapy is still to
be defined. In Europe, chemotherapy has now been
adopted subsequent to the ESPAC trial [28], whereas
in the USA, chemoradiotherapy is the standard
adjuvant therapy [29,30]. Although debate is on-
going, it has become clear that adjuvant therapy is
beneficial. This may be a rational explanation for the
difference in survival between the two groups of
patients.
In conclusion, although an increasing nomogram
score is associated with poorer survival, the accuracy
demonstrated by MSKCC could not be replicated in
the current cohort of patients. This may reflect
differences in patient demographics, accuracy of
pathological staging and differences in treatment
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Figure 4. Effect of total nomogram score on survival (Edinburgh).
Table II. Analysis of prognostic variables.
Variable n Median survival p (univariate analysis) p (multivariate analysis)
Positive lymph nodes Yes 45 297 (194471) 0.005 0.006
No 18 367 (3081060)  
Posterior resection margin positive Yes 20 210 (146443) 0.024 0.20
No 43 355 (265835)  
Resection margin positive Yes 24 301 (154448) 0.26 
No 39 352 (248834)  
Tumour size 2 cm Yes 14 471 (300847) 0.12 
No 39 309 (202448)  
Poorly differentiated Yes 30 308 (157402) 0.89 
No 33 393 (228834)  
Median nomogram score 5217 32 367 (295847) 0.15 0.36
217 31 265 (157443)  
N
om
og
ra
m
 sc
or
e
(M
ed
ian
 E
din
bu
rgh
 Sc
ore
 – 
21
7)
24% 8% 44%
15% 28% 
150
200
250
300
350
0 10 20 30 40 50 60 70
% survival predicted by nomogram 
63% 
Predicted 3 year survival by nomogram  
Predicted 2 year survival by nomogram 
Predicted 1 year survival by nomogram 
Actual 1 year survival
(Edinburgh patients) 
Actual 2 year survival  
(Edinburgh patients)  
Actual 3 year survival  
(Edinburgh patients)  
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regimens between the two centres. This emphasises
the importance of national development of nomo-
grams for the practice patterns of an institution or a
country. The MSKCC nomogram has been success-
fully validated in another US institution [31] although
this is the first study evaluating the nomogram in a
tertiary referral centre in the UK.
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